Advertisement
ACRV vs CRMD
Which Stock Would AI Choose? Acrivon Therapeutics (ACRV) vs. CorMedix (CRMD) Stock Comparison
Key Takeaways
- Acrivon Therapeutics (ACRV) is a pre-revenue, clinical-stage precision-oncology developer whose shares trade near or below the value of its cash reserves.
- CorMedix (CRMD) is a commercial-stage biopharmaceutical company generating meaningful revenue and net income from its DefenCath catheter lock solution and Melinta portfolio.
- The two stocks represent contrasting risk profiles: ACRV offers high-risk, catalyst-driven upside, while CRMD offers a revenue-generating base with nearer-term pipeline catalysts.
- Recent market activity shows both names trading well below their 52-week highs, but for different underlying reasons.
- CRMD has raised its full-year revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance, while ACRV's value hinges on upcoming clinical data readouts.
- For more context on each company, explore ACRV Major News and ACRV Today's Price Move, as well as CRMD Major News and CRMD Today's Price Move.
- To see how quantitative systems are positioning across the market, explore Trending AI Robots.
Introduction
This stock comparison examines two healthcare names at very different stages of development. ACRV (Acrivon Therapeutics) is an early-stage precision-oncology company with no product revenue, while CRMD (CorMedix) is a commercial-stage biopharmaceutical firm already generating substantial sales. Comparing them highlights the trade-off between speculative clinical upside and established revenue generation — a distinction relevant to both long-term investors assessing market positioning and traders monitoring relative performance and sentiment shifts.
ACRV Overview and Recent Performance
Acrivon Therapeutics develops oncology medicines matched to patients predicted to respond using its proprietary AP3 phosphoproteomics platform. Its lead asset, ACR-368 (prexasertib), is a CHK1/CHK2 inhibitor in a registrational-intent Phase 2b trial for endometrial cancer. Recent interim data showed a confirmed overall response rate of roughly 52% in serous endometrial cancer patients versus 22% in non-serous patients.
In recent weeks, the stock has remained pressured, trading near the lower end of its 52-week range and below its cash position. The company reported a first-quarter net loss of approximately $19 million and held about $97.7 million in cash and investments as of late March, which management expects to fund operations into the third quarter of 2027. Because the company is pre-revenue, sentiment has been driven primarily by clinical catalysts, financing activity, and cash-burn concerns rather than fundamentals.
CRMD Overview and Recent Performance
CorMedix is a commercial-stage biopharmaceutical company focused on therapies for life-threatening conditions. Its flagship product, DefenCath (taurolidine and heparin), is an FDA-approved antimicrobial catheter lock solution used in hemodialysis, and its August 2025 acquisition of the Melinta portfolio added a second revenue stream.
Recent financial results have been notably strong: first-quarter net revenue reached approximately $127.4 million with net income of $38.6 million, prompting management to raise full-year revenue guidance to a range of $325 million to $345 million and adjusted EBITDA guidance. Despite this, shares have declined roughly 30% year-to-date, reflecting investor concerns about a pending reimbursement transition (the TDAPA step-down) and broader sector pressure. Recent weeks also brought the FDA acceptance of a supplemental new drug application for Rezzayo in preventing invasive fungal disease.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, but only a select group earns placement in the curated Trending AI Robots section. These bots are screened for their suitability to current market conditions, drawing on diverse trading styles, strategies, timeframes, performance statistics, and ticker universes. The section highlights bots with competitive track records and measurable statistics, helping traders evaluate systems that align with their own objectives. Exploring the Trending AI Robots page offers a practical way to see which strategies are currently favored by quantitative models.
Head-to-Head Comparison
The most fundamental contrast is the stage of commercialization. CRMD has an approved, revenue-generating product and a growing anti-infective franchise, while ACRV is pre-revenue and dependent on clinical milestones. This produces very different growth drivers: CRMD's value is tied to DefenCath utilization, reimbursement dynamics, and the Melinta integration, whereas ACRV's is tied to trial readouts and platform validation.
Risk profiles diverge sharply as well. ACRV faces binary clinical risk and ongoing financing needs, while CRMD faces commercial and reimbursement risk, including a second-half pricing transition and a securities class action in active discovery. On market positioning, ACRV trades below cash with a micro-cap valuation, whereas CRMD is meaningfully larger and profitable but still trades well below its highs. Recent momentum has been challenged in both names, though CRMD's setbacks occurred despite earnings beats and raised guidance, while ACRV's reflect continued discounting of its pipeline.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor CRMD at present. Its combination of positive revenue trends, profitability, raised guidance, a strong cash position, and defined near-term catalysts (including the Rezzayo sNDA acceptance) reflects greater trend consistency and stability than ACRV's pre-revenue, catalyst-dependent profile. That said, ACRV's clinical data could drive substantial re-rating if subsequent readouts confirm early response rates. The AI's preference is therefore probabilistic rather than definitive, weighting current fundamentals and relative stability over speculative upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRV is a Hold and CRMD is a Hold.
Momentum Indicator for ACRV turns negative, indicating new downward trend
ACRV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 67 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 30 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRV's RSI Indicator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.498). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CRMD's RSI Indicator is remaining in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 230 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMD as a result. In 79 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CRMD turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
CRMD moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CRMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.900) is normal, around the industry mean (3.498). P/E Ratio (2.163) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
CRMD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 96 | |
SMR RATING 1..100 | 19 | |
PRICE GROWTH RATING 1..100 | 82 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ACRV | CRMD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 73% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 83% |
| Advances ODDS (%) | 8 days ago 89% | 3 days ago 81% |
| Declines ODDS (%) | 2 days ago 88% | 10 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRV’s FA Score shows that 0 FA rating(s) are green while CRMD’s FA Score has 1 green FA rating(s).
- ACRV’s FA Score: 0 green, 5 red.
- CRMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRV’s TA Score shows that 4 TA indicator(s) are bullish while CRMD’s TA Score has 4 bullish TA indicator(s).
- ACRV’s TA Score: 4 bullish, 6 bearish.
- CRMD’s TA Score: 4 bullish, 6 bearish.
Price Growth
ACRV (@Biotechnology) experienced а -5.99% price change this week, while CRMD (@Biotechnology) price change was -3.42% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
ACRV is expected to report earnings on Nov 12, 2026.
CRMD is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACRV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACRV has been loosely correlated with IMRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRV jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To ACRV | 1D Price Change % | ||
|---|---|---|---|---|
| ACRV | 100% | -0.63% | ||
| IMRX - ACRV | 51% Loosely correlated | +5.48% | ||
| ALLR - ACRV | 48% Loosely correlated | -3.49% | ||
| CRMD - ACRV | 43% Loosely correlated | -1.83% | ||
| DNA - ACRV | 41% Loosely correlated | -2.91% | ||
| SANA - ACRV | 38% Loosely correlated | -1.42% | ||
More | ||||
CRMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with IMRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To CRMD | 1D Price Change % | ||
|---|---|---|---|---|
| CRMD | 100% | -1.83% | ||
| IMRX - CRMD | 48% Loosely correlated | +5.48% | ||
| ABOS - CRMD | 45% Loosely correlated | -2.95% | ||
| ACRV - CRMD | 43% Loosely correlated | -0.63% | ||
| GYRE - CRMD | 36% Loosely correlated | -9.03% | ||
| PMN - CRMD | 35% Loosely correlated | -1.73% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IMF | 52.12 | 0.42 | +0.81% |
| Invesco Managed Futures Strategy ETF (IMF) | |||
| MAYC | 26.38 | N/A | N/A |
| Corgi U.S. Equities 10% Structured Buffer ETF (MAYC) | |||
| PPTY | 33.30 | -0.13 | -0.40% |
| US Diversified Real Estate ETF (PPTY) | |||
| VTWG | 258.74 | -2.21 | -0.85% |
| Vanguard Russell 2000 Growth ETF (VTWG) | |||
| BPRO | 18.84 | -0.52 | -2.69% |
| Bitwise Proficio Currency Debasement ETF (BPRO) | |||